ASCVD
Clinical trials for ASCVD explained in plain language.
Never miss a new study
Get alerted when new ASCVD trials appear
Sign up with your email to follow new studies for ASCVD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to melt artery plaque in heart patients
Disease control Recruiting nowThis study tests an experimental drug called ABP-745 in 200 adults with atherosclerosis (hardening of the arteries from plaque buildup). The goal is to see if it can reduce plaque in the arteries better than a placebo over 52 weeks. Participants must already be on cholesterol-low…
Matched conditions: ASCVD
Phase: PHASE2 • Sponsor: Atom Therapeutics Co., Ltd • Aim: Disease control
Last updated May 26, 2026 06:33 UTC
-
Heart drug trial targets Gene-Linked inflammation
Disease control Recruiting nowThis study tests whether the drug canakinumab can reduce inflammation in the blood vessels of people with a history of heart disease. Some participants have a specific gene change (TET2) that may increase inflammation. The study involves 120 adults and compares canakinumab to a p…
Matched conditions: ASCVD
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 06:23 UTC
-
Massive trial tests which diabetes drug better shields heart and kidneys
Disease control Recruiting nowThis study compares two common diabetes medications (SGLT2 inhibitors and GLP-1 receptor agonists) to see which is better at preventing heart attacks, strokes, kidney failure, and death in people with type 2 diabetes who already have or are at high risk for heart disease. About 6…
Matched conditions: ASCVD
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
Arm cuff therapy may shield organs in High-Risk heart patients
Disease control Recruiting nowThis study tests whether a non-invasive procedure called remote ischemic conditioning (RIC) can reduce the risk of heart attacks, strokes, kidney problems, and death in people with very high-risk atherosclerotic cardiovascular disease (ASCVD). About 2,800 participants over age 40…
Matched conditions: ASCVD
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated May 20, 2026 11:55 UTC